Toll Free: 1-888-670-5445
Suite 101, 2011-94 St. Edmonton, AB T6N 1H1 Canada
"InnovoSCEPT™ biofilm susceptibility testing" ) This breakthrough test allows doctors and veterinarians to make better choices for antibiotics to treat serious chronic biofilm infections.
"InnovoSIL™ antimicrobial products" are a family of novel agents ideally suited for use with medical devices such as wound dressings, urinary and blood system catheters and in other situations where control of bacteria on a surface is required.
These unique antimicrobial agents minimize the chances of hospital-acquired infections (HAIs) that are primarily caused by the procedures related to medical devices. Examples are the insertion of urinary and blood system catheters.
HAIs are responsible for 99,000 deaths annually at a health care cost of $33 billion.
The US National Institute of Health estimates that greater than 80% of clinical infections are caused by biofilms. This includes heart and middle ear infections, wound infections, and illnesses associated with implanted medical devices as well as tooth decay and gum disease.
Innovotech's matrix driven experimental systems allow for rapid high throughput screening and antimicrobial R&D for a variety of systems and applications. The MBEC™ assay and the BEST™ system can be used for investigating disinfectants, antimicrobial coatings, and many other applications covering the full range from development through regulatory submission to post-market analysis.
New Silver Technology Kills Biofilms
January 10, 2012,
The Cutting Edge: Where BioMed and BioTech Intersect
September 28, 2011
World Talk Radio website
"Innovotech product wins international seal of approval",
April 21, 2011
Receive an e-mail containing the full text of the news release as they are published. Click here to Receive News Releases